GLP-1s and My Thyroid Medication: The Warning, and the Part Nobody Mentioned

Two thyroid questions, and I only knew about one

I have taken levothyroxine every morning since a few months after my second baby. Little pill, empty stomach, coffee half an hour later, done. It is the most boring thing about my health and I had stopped thinking about it.

Then I filled in an intake form for a GLP-1, found thyroid questions on it, and realised I did not know what they were asking or why. There are two of them. Everywhere I looked they were mashed together, and they have nothing to do with each other.

Question one: the boxed warning

Every one of these drugs carries the same warning at the top of its label, in a box — the strongest form the FDA uses.

Zepbound's says that in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures; that it is unknown whether Zepbound causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined¹. Wegovy's is the same shape, with semaglutide and "in rodents" in place of rats².

Both are contraindicated if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2¹² — that is what the intake form screens for. The symptoms both labels say to know are a lump in the neck, trouble swallowing, shortness of breath and hoarseness that will not go away¹.

Neither softer nor harder than written, then: a rodent finding, human relevance stated as not determined, an absolute contraindication for those two histories — and both labels saying routine calcitonin monitoring and thyroid ultrasound are of uncertain value for catching MTC early¹². The answer to being worried is not more screening, which is not what I expected.

And it is medullary thyroid carcinoma and MEN 2, not "thyroid disease". Ordinary hypothyroidism, Hashimoto's, the levothyroxine in my cupboard: none of it appears there.

Human data exist and are reassuring rather than conclusive. A Scandinavian cohort followed 145,410 people who started a GLP-1 against 291,667 who started a DPP-4 inhibitor: 76 thyroid cancers versus 184, a hazard ratio of 0.93 with a confidence interval of 0.66 to 1.31, over a mean 3.9 years³. The authors' own framing is the one I trust — the upper limit is consistent with no more than a 31% increase in relative risk. For medullary thyroid cancer the interval was too wide to say anything: 0.37 to 3.86³.

Question two: my actual thyroid pill, which I got completely backwards

I assumed the problem would be absorption: these drugs slow your stomach down, so surely my levothyroxine would sit there and never get in.

It is the other direction, and narrower than I thought. Wegovy's label reports a drug-interaction study using the semaglutide tablet in which levothyroxine exposure went up by 33%, not down — and says that in the trials of the 1 mg once-weekly injection, semaglutide did not affect the absorption of orally administered medicines at all².

Zepbound's label does not name levothyroxine anywhere; I looked. It carries a general caution that delayed gastric emptying may affect absorption of oral medications, and says to monitor anyone on a drug with a narrow therapeutic index — its example is warfarin¹. Levothyroxine has a narrow index too, so nobody has run the study on my exact combination.

The part nobody mentioned to me

What I wish someone had said on day one has nothing to do with absorption.

Levothyroxine is dosed by body weight. Lose a meaningful amount of weight and the dose that was right for you can become too much for you.

One published case made me sit up: a 52-year-old woman, post-thyroidectomy and stable on levothyroxine for years, started tirzepatide, lost 48 pounds over six months, and turned up dizzy, tachycardic, weak and confused with a markedly suppressed TSH and a high free T4 — significantly over-replaced, needing an urgent dose reduction⁴. One case report, not a rate, and she had no thyroid of her own to buffer anything. But the mechanism is not exotic.

Then the study that annoyed me. Researchers matched 5,370 Medicare patients on a stable levothyroxine dose and compared starting a GLP-1 against starting an SGLT-2 inhibitor. About 83% of both groups had a TSH test within the year, at a mean of roughly 130 days — identical⁵. The drug that causes substantial weight loss made nobody check the thyroid dose sooner. That was an older group with type 2 diabetes, not moms in their thirties, and it still tells me the recheck is not automatic.

What I did, and when I would call

I asked for a TSH about three months in, and again once I had lost enough that my jeans were a joke. I kept the levothyroxine exactly where it has always been — first thing, empty stomach, away from everything else — because there is every reason not to add a variable. The rest of the women's side-effect list sits alongside this one.

Do not wait for a scheduled recheck if you get a racing heart, a tremor, feeling hot when nobody else is, real insomnia, or anxiety that feels chemical rather than earned. Those are over-replacement symptoms, and on this drug they are easy to write off as the medication or as tiredness. And call about a new lump in your neck, hoarseness that does not clear, or trouble swallowing — that is the boxed-warning list, and it is not a wait-and-see.

I am a mom who takes this medication and reads the research, not a clinician. This is education, not medical advice.

Where I landed

My endocrinologist was completely unbothered by the combination, which is the correct response to two conditions with nothing to do with each other. What she was not unbothered by was the dose.

That is the conversation worth having, and it is the one I nearly did not have — because I was busy worrying about the box at the top of the label instead.